Table 1 Potential action of the Lp-PLA2 , according to studies with distinct design.
From: Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2 ): a review
Study design | Action | Reference |
|---|---|---|
Experimental | Cells ROS protection. | [33] |
Experimental | ↓ bioactivity phospholipids in oxLDL | [37] |
Experimental | ↓ oxidized phospholipids in mildly oxLDL | [38] |
Case/Control | ≈ Oxidized phospholipids and anti-Lp-PLA2 | [41] |
Case/Control | ↓ HDL oxidation, foam cell and autoantibodies titers. | [42] |
Case/Control | ↓ HDL-Lp-PLA2 activity | [25] |
Case/Control | ↓ HDL-Lp-PLA2 activity | [60] |
Case/Control | ↑ LDL-Lp-PLA2 to HDL-Lp-PLA2 ratio | [31] |
Case/Control | ↓ HDL-Lp-PLA2 and ↑ of LDL-Lp-PLA2 | [56] |
Case/Control | ≈ Lp-PLA2 activity | [55] |
Case/Control | ↑ Lp-PLA2 activity | [61] |
Cohort | ↑ Lp-PLA2 activity in CHD mortality | [62] |
Case/Control | ↑ Lp-PLA2 activity | [63] |
Cohort | Predictor of cardiovascular outcomes | [4] |
Cohort | Lp-PLA2 correlated with cardiovascular risk factors | [64] |
Cohort | Lp-PLA2 activity associated with MS and CVD | [5] |
Cohort | Lp-PLA2 mass and activity associated with CVD | [65] |
Cohort | ↑ Lp-PLA2 activity associated with CVD | [6] |
Meta-analysis | Lp-PLA2 mass and activity associated vascular risk | [66] |